



# MEDIA RELEASE

**For immediate release**

Tuesday 29 June 2021

## **4DMedical commences COPD-focused clinical trial with Johns Hopkins School of Medicine**

A second clinical trial validating the clinical application of 4DMedical's XV Technology has commenced at Johns Hopkins University in Baltimore, one of the world's most renowned centres of research translation.

The trial underway is focusing on application of 4DMedical's patented XV Technology to Chronic Obstructive Lung Disease (COPD), a collective term for progressive lung diseases including emphysema and chronic bronchitis, resulting in the chronic obstruction of airflow in the lungs.

"COPD represents one of the largest use cases for our *XV LVAS* technology, with the disease affecting around 3.2 percent of the global population," said 4DMedical Managing Director and Chief Executive Officer, Dr Andreas Fouras.

"Given the requirement of clinicians to monitor changes in patients' airflow frequently, the lower radiation exposure using *XV LVAS* makes it a preferable diagnostic tool for COPD monitoring compared to existing modalities," Dr Fouras added. "Accounting for close to 5.7 percent of global deaths, COPD is the third largest cause of death in the world, so the potential for 4DMedical to play a role in disease diagnosis and surveillance is significant, along with our capacity to monitor pharmaceutical interventions."

4DMedical's extensive program of clinical trials and pilot studies positions the company to capture a sizeable portion of the global respiratory diagnostic market, validating application of its technology to the world's most prevalent and costly lung diseases.

"Johns Hopkins University is recognised and respected as one of the world's great biomedical research institutions," said 4DMedical's Vice President Medical and Clinical Affairs, Dr Jason Kirkness, a former assistant professor of pulmonary and critical care medicine at Johns Hopkins.

<more>

“The respect afforded our company and its capabilities is reflected through the stature of clinical trial partners such as Duke University Hospital, Oregon Health & Science University, and the Vanderbilt University Medical Centre,” Dr Kirkness added. “4DMedical is privileged and proud to collaborate with many of the world's most reputable research universities.”

Trial results are expected to be published in independent medical journals later this year.

<ends>

## **CONTACT**

Clint Rodgers; Vice President Marketing and Communications: +61 422378131 / +61 428587350  
(24 hours)

## **PRODUCT INFORMATION**

<https://4dmedical.com/our-products/clinical/>

## **BACKGROUNDER**

4DMedical is a medical technology company transforming respiratory diagnostics for all lung disorders including coronavirus, asthma, chronic obstructive pulmonary disease (COPD), cystic fibrosis and cancer.

Through its technology 4DMedical is providing clinicians with greater insights into diseases of the lung, 4DMedical is focusing on providing better information to doctors and patients about lung function.

The unique 4DMedical technology accurately and quickly scans lung function as the patient breathes, assisting in providing sensitive, early diagnosis, and to monitor changes over time. The company's Software-as-a-Service (SaaS)-enabled scans deliver much more complete results, showing even subtle variations in lung function down to the finest details, using lower and safer levels of radiation than traditional methods.

Better information means better decisions, and better outcomes.

Based in Melbourne, Australia and Los Angeles, USA, 4DMedical was founded in 2012 and is listed on the Australian Securities Exchange (ASX: 4DX).

**4dmedical.com**

Melbourne, Australia

Los Angeles, USA